Study suggests acetaminophen exposure in pregnancy linked to higher risk of ADHD and autism

Nov 04, 2019

Exposure to acetaminophen in the womb may increase a child’s risk for attention deficit/hyperactivity disorder and autism spectrum disorder, suggests a study funded by the National Institutes of Health and the Agency for Health Care Research and Quality. The study was conducted by Xiaobing Wang MD, of the Johns Hopkins University Bloomberg School of Public Health, Baltimore, and colleagues. It appears in JAMA Psychiatry.

Attention deficit/hyperactivity disorder (ADHD) is marked by a pattern of hyperactivity and impulsive behavior. Autism spectrum disorder is a complex developmental disorder that affects how a person behaves, interacts with others and learns.

Researchers analyzed data from the Boston Birth Cohort, a long-term study of factors influencing pregnancy and child development. They collected umbilical cord blood from 996 births and measured the amount of acetaminophen and two of its byproducts in each sample. By the time the children were an average of 8.9 years, 25.8% had been diagnosed with attention deficit/hyperactivity disorder only, 6.6% with autism spectrum disorder only, and 4.2% with attention deficit/hyperactivity disorder and autism spectrum disorder. The researchers classified the amount of acetaminophen and its byproducts in the samples into thirds, from lowest to highest. Compared to the lowest third, the middle third of exposure was associated with about 2.26 times the risk for attention deficit/hyperactivity disorder. The highest third of exposure was associated with 2.86 times the risk. Similarly, autism spectrum disorder risk was higher for those in the middle third (2.14 times) and highest third (3.62 times).

The authors conclude that their results support earlier studies linking acetaminophen exposure in the womb with attention deficit/hyperactivity disorder and autism spectrum disorder and underscore the need for additional research. The U.S. Food and Drug Administration urges careful consideration before using any pain-relieving medication during pregnancy.

NIH funding for the study was provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Allergy and Infectious Diseases and the National Institute of Environmental Health Sciences.

Source: News Release
National Institutes of Health (NIH)
October 30, 2019